chronic kidney disease
Conditions
Interventions
control subjects:Basic treatment ((including diet, improvement of living habits and pharmacological treatment to reduce proteinuria, control blood pressure and blood lipids, correct anaemia, correct h
Suyin Group:Basic treatment ((including diet, improvement of living habits and pharmacological treatment to reduce proteinuria, control blood pressure and blood lipids, correct anaemia, correct hyperu
Suyin Antidote Granules
Suyin Shenkang Group:Basic treatment ((including diet, improvement of living habits and pharmacological treatment to reduce proteinuria, control blood pressure and blood lipids, correct anaemia, corre
nephrotic suppository
Sponsors
Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic and staging criteria for CKD stages 3-5 set by KDIGO is not admitted to dialysis and is identified in Chinese medicine as renal deficiency and turbidity Toxicity evidence; 2. Aged between 18 years old and 80 years old gender is not limited; 3. Infection acidosis electrolyte disorders hypertension hyperlipidaemia etc. are effectively controlled; 4. Informed consent voluntary subjects.The process of obtaining informed consent should be in accordance with GCP regulations.
Exclusion criteria
Exclusion criteria: 1. Use of renal failure granules uremic acid granules and proprietary Chinese medicines with renal-protective effects developed by outside hospitals during the treatment period. 2. Own combined intestinal diseases (e.g. inflammatory bowel disease etc.) or those who have undergone intestinal surgery (e.g. colorectal tumour resection enterostomy etc.) 3. Have used Chinese medicine enema treatment after the current onset of illness. 4. Women during pregnancy and lactation. 5. Have a combination of serious primary diseases of the heart brain liver and haematopoietic system or other serious diseases that affect their survival. 6. Those who are unable to give full informed consent due to intellectual or behavioural disabilities. 7. Suspected or confirmed history of alcohol or drug abuse. 8. Other medical conditions that in the judgement of the investigator reduce the likelihood of enrolment or complicate enrolment e.g. frequent changes in the work environment that could lead to missed visits. 9. Allergy such as a history of allergy to two or more drugs or foods; or known allergy to the ingredients of the drug. 10. Patients who are participating in clinical trials of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| asymmetric dimethylarginine;paraccresol sulfate;glomerular filtration rate;creatinine;ß2-microglobulin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chinese Medicine Kidney Deficiency Turbid Toxin Evidence Symptom Score;albumin;haematuria;cholesterol;24-hour urine protein quantification;blood lipids;Cystatin C;urea nitrogen; | — |
Countries
China
Contacts
Public ContactZhou Enchao
Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine)
Outcome results
None listed